These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

919 related articles for article (PubMed ID: 22691239)

  • 1. Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.
    Al Shaer L; AbdulRahman M; John TJ; AlHashimi A
    Transfusion; 2012 Nov; 52(11):2300-9. PubMed ID: 22691239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
    Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
    Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
    Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
    Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
    Hourfar MK; Jork C; Schottstedt V; Weber-Schehl M; Brixner V; Busch MP; Geusendam G; Gubbe K; Mahnhardt C; Mayr-Wohlfart U; Pichl L; Roth WK; Schmidt M; Seifried E; Wright DJ;
    Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.
    O'Brien SF; Yi QL; Fan W; Scalia V; Kleinman SH; Vamvakas EC
    Transfusion; 2007 Feb; 47(2):316-25. PubMed ID: 17302779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services.
    O'Brien SF; Yi QL; Fan W; Scalia V; Fearon MA; Allain JP
    Vox Sang; 2012 Jul; 103(1):83-6. PubMed ID: 22289147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.
    Shang G; Seed CR; Wang F; Nie D; Farrugia A
    Transfusion; 2007 Mar; 47(3):529-39. PubMed ID: 17319836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating window period blood donations for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus by nucleic acid amplification testing in Southern Pakistan.
    Moiz B; Moatter T; Shaikh U; Adil S; Ali N; Mahar F; Shamsuddin N; Khurshid M
    Transfusion; 2014 Jun; 54(6):1652-9. PubMed ID: 24383918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety?
    Stramer SL; Notari EP; Krysztof DE; Dodd RY
    Transfusion; 2013 Oct; 53(10 Pt 2):2449-58. PubMed ID: 23607261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing.
    Offergeld R; Faensen D; Ritter S; Hamouda O
    Euro Surveill; 2005 Feb; 10(2):8-11. PubMed ID: 15735310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand.
    Nantachit N; Thaikruea L; Thongsawat S; Leetrakool N; Fongsatikul L; Sompan P; Fong YL; Nichols D; Ziermann R; Ness P; Nelson KE
    Transfusion; 2007 Oct; 47(10):1803-8. PubMed ID: 17880604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000.
    Chiavetta JA; Escobar M; Newman A; He Y; Driezen P; Deeks S; Hone DE; O'Brien SF; Sher G
    CMAJ; 2003 Oct; 169(8):767-73. PubMed ID: 14557314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing)].
    Pillonel J; Laperche S; ; ;
    Transfus Clin Biol; 2004 Apr; 11(2):81-6. PubMed ID: 15120104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.
    Busch MP; Glynn SA; Stramer SL; Strong DM; Caglioti S; Wright DJ; Pappalardo B; Kleinman SH;
    Transfusion; 2005 Feb; 45(2):254-64. PubMed ID: 15660836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy.
    Gonzalez M; Règine V; Piccinini V; Vulcano F; Giampaolo A; Hassan HJ
    Transfusion; 2005 Oct; 45(10):1670-5. PubMed ID: 16181219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of triplex nucleic acid test assays in United States blood donors.
    Stramer SL; Krysztof DE; Brodsky JP; Fickett TA; Reynolds B; Dodd RY; Kleinman SH
    Transfusion; 2013 Oct; 53(10 Pt 2):2525-37. PubMed ID: 23550838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does prevalence of transfusion-transmissible viral infection reflect corresponding incidence in United States blood donors?
    Wang B; Schreiber GB; Glynn SA; Kleinman S; Wright DJ; Murphy EL; Busch MP;
    Transfusion; 2005 Jul; 45(7):1089-96. PubMed ID: 15987352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing.
    Zou S; Dorsey KA; Notari EP; Foster GA; Krysztof DE; Musavi F; Dodd RY; Stramer SL
    Transfusion; 2010 Jul; 50(7):1495-504. PubMed ID: 20345570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.
    Bruhn R; Lelie N; Busch M; Kleinman S;
    Transfusion; 2015 Jun; 55(6):1195-205. PubMed ID: 25727549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of the risk of transfusion-transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: a 5-year review.
    Cable R; Lelie N; Bird A
    Vox Sang; 2013 Feb; 104(2):93-9. PubMed ID: 22924987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.